Disclosures: Luca Fabris: Nothing to Disclose, Camilla Venturin: Nothing to Disclose, Yahima Frin-Herrera: Nothing to Disclose, Massimiliano Cadamuro: Nothing to Disclose, Claudia Mescoli: Nothing to Disclose, Umberto Cillo: Nothing to Disclose, Enrico Gringeri: Nothing to Disclose, Elena Campello: Nothing to Disclose, Mario Strazzabosco: Nothing to Disclose, Diego Calvisi: Nothing to Disclose, Antonio Cigliano: Nothing to Disclose, Paolo Simioni: Nothing to Disclose 1938 TRANSPOSON-BASED ONCOGENES INTEGRATION IN ABCB4 (MDR2)-/- MICE RECAPITULATES HIGH SUSCEPTIBILITY TO CHOLANGIOCARCINOMA IN PRIMARY SCLEROSING CHOLANGITIS Pinzhu Huang 1 Guangyan Wei 1 Jesse Kirkpatrick 2 MARAM ALENZI 1 Yi Lin 1 Li Tan 1 Disha Badlani 1 Li Chen 3 Mathieu Petitijean 3 Kahini Vaid 1 Shuangshuang Zhao 1 Alicia lugovskoy 1 Xin Chen 4 Gregory Gores 4 Yury Popov 1 , 1 Division of Gastroenterology and Hepatology, BIDMC, Harvard Medical School, 2 Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 3 PharmaNest, Inc, NJ, 4 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN Background: Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC), difficult to diagnose and associated with high mortality
First, magnets were placed in the receiver cell, and it was filled with 0.01 M PBS
All Arencia products are 100% made in Korea
J Biol Chem 268:1421514223 Dominguez-Alvarez E, Plano D, Font M, Calvo A, Prior C, Jacob C, Palop JA, Sanmartin C (2014) Synthesis and antiproliferative activity of novel selenoester derivatives
